JULY 28, 2014
July 28, 2014, Vancouver, BC – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWD – OTC) (“SL” – CSE) is pleased to report that in respect to its previously announced intention to consolidate its issued and outstanding share capital on the basis of five (5) current shares for one (1) new share, its shares will begin trading on a consolidated basis and with a new CUSIP number on July 31, 2014. The name and symbol will not change.
No fractional shares will be issued but will be rounded to the nearest whole number.
As a result, the outstanding common shares of the Company will be reduced to approximately 59,184,637 shares.
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completetion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.